Medical Crossfire™: Improving Patient Outcomes in TNBC: Immunotherapy, PARP, TROP2, Oh My!

A PER satellite symposium in conjunction with the 2023 Annual Oncology Meeting.

Program Description

The past few years have realized approvals of several new targeted drugs for triple-negative breast cancer (TNBC) based on our increased understanding of the diverse genetic etiologies underlying this disease. Immune checkpoint inhibition plays a key role throughout the course of TNBC, with ongoing trials evaluating new combination regimens. The use of PARP inhibitors has greatly expanded in the treatment of patients with BRCA1/2-mutated TNBC. In addition, the recent development of novel TROP2-directed antibody-drug conjugate has transformed the treatment of metastatic TNBC. With the growing armamentarium of treatment options, it is critical to examine recent clinical developments of these oncogenic targeted therapies and appreciate the implications for the treatment of early-stage and metastatic TNBC.

In conjunction with the 2023 ASCO Annual Meeting, this in-person and virtual satellite symposium will provide multiple perspectives on hot topics with spirited case-based panel discussions. This activity will help health care professionals maintain their clinical practice by providing expert guidance on how to incorporate the latest clinical efficacy and safety data on immunotherapies, PARP- and TROP2-targeted therapies for the treatment of TNBC.

Target audience: This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other health care professionals involved in the treatment of TNBC.

Type of activity: Application
Release date: June 2, 2023
Expiration date: August 2, 2023

Time to complete activity: 2.0 hours

Learner level: Intermediate, Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Determine the biologic subtypes of triple-negative breast cancer (TNBC) and the use of validated biomarkers to develop individualized treatment plans incorporating targeted therapeutics for appropriate patients
• Implement evidence-based treatment planning for patients with TNBC, incorporating efficacy and safety data from clinical trials evaluating immunotherapies, PARP inhibitors, antibody drug conjugates, and cytotoxic agents
• Design strategies to monitor for and manage adverse events to mitigate their impact on outcomes among patients receiving treatment for TNBC
• Discuss ongoing clinical trials of investigational agents for TNBC and the placement of emerging data in the context of current treatment paradigms

Not an official event of the 2023 ASCO Annual Meeting.
Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-23-230-L01-P. The activity is available for CE credit through August 2, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Ronny Viggiani, MD; Steve Nair MD; Mikaela Rossi, and Kylie Ferrentino.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms